Lead Product(s): Nivolumab
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IV Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 29, 2020
The trial demonstrated encouraging response rates and duration of response with Opdivo in SCLC, an aggressive and difficult-to-treat cancer.